Covid vaccine tests at nursing homes
Eli Lilly began testing its Covid-19 antibody drug in nursing homes in the US, a treatment with potential to protect vulnerable groups that vaccines may not cover. The trial, dubbed Blaze-2, marks the third phase of testing for the monoclonal antibody that Lilly co-developed with Canadian start-up AbCellera Biologics. It will enrol up to 2,400 participants who are either diagnosed with Covid-19 or at the risk of exposure. Meanwhile, rival drugmakers AbbVie, Amgen, and Takeda said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against Covid-19.